Literature DB >> 15337217

Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus.

Meenakshi A Bhalla1, Audrey Chiang, Victoria A Epshteyn, Radmila Kazanegra, Vikas Bhalla, Paul Clopton, Padma Krishnaswamy, L K Morrison, Albert Chiu, Nancy Gardetto, Sunder Mudaliar, Steven V Edelman, Robert R Henry, Alan S Maisel.   

Abstract

OBJECTIVES: We hypothesized that B-type natriuretic peptide (BNP) levels can predict cardiac mortality in diabetic patients.
BACKGROUND: Detection of cardiovascular disease in diabetics can be difficult until overt events occur.
METHODS: A total of 482 diabetics (majority male with type 2 diabetes) at the Veterans Affairs Medical Center San Diego were divided into two groups: 1) referred patients for echocardiogram on the basis of clinical suspicion of cardiac dysfunction (referred [R], n = 180); 2) patients randomly selected from the diabetic clinic without any suspicion of cardiac dysfunction (not referred [N-R], n = 302). We examined cardiac events and all-cause mortality in relation to initial BNP levels during the follow-up.
RESULTS: A total of 71 (14.7%) patients died during this period: 52 of 180 (29%) in the R group (30 of 52 [58%] cardiac, 10 of 52 [19%] non-cardiac, 2 of 52 [4%] renal, 10 of 52 [19%] unknown cause) and 19 of 302 (6%) in N-R group (6 of 19 [32%] cardiac). The median BNP level in the R and N-R groups who died of cardiac, non-cardiac, and unknown cause was 537 and 87, 80 and 53, and 343 and 38 pg/ml, respectively. The receiver-operating characteristic (ROC) values for mortality in two groups in relation to BNP revealed the area under the curve to be 0.720 and 0.691, respectively (p < 0.01 in both). Among commonly used prognostic indicators in diabetics, only the ROC for triglycerides was significant. The most accurate cut-point in both the N-R group (87%) and R group (61%) was 120 pg/ml of BNP. Cox regression analysis showed BNP to be the most significant predictor of all-cause mortality in the R group. There was a marked decrease in survival in the patient group with BNP >120 pg/ml.
CONCLUSIONS: B-type natriuretic peptide appears to be a reliable predictor of future cardiac and all-cause mortality in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337217     DOI: 10.1016/j.jacc.2004.05.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  20 in total

1.  The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial.

Authors:  M D Witham; F J Dove; M Dryburgh; J A Sugden; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2010-07-02       Impact factor: 10.122

2.  Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.

Authors:  L Tarnow; M-A Gall; B V Hansen; P Hovind; H-H Parving
Journal:  Diabetologia       Date:  2006-08-26       Impact factor: 10.122

3.  Neurohormonal profile of patients with heart failure and diabetes.

Authors:  I C C van der Horst; R A de Boer; H L Hillege; F Boomsma; A A Voors; D J van Veldhuisen
Journal:  Neth Heart J       Date:  2010-04       Impact factor: 2.380

4.  B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes.

Authors:  B S Rana; J I Davies; M M Band; S D Pringle; A Morris; A D Struthers
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

5.  B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?

Authors:  Omer Karadag; Meral Calguneri; Bunyamin Yavuz; Enver Atalar; Ali Akdogan; Umut Kalyoncu; Sedat Kiraz; Serdar Aksoyek; Ferhan Ozmen; A Ihsan Ertenli
Journal:  Clin Rheumatol       Date:  2007-02-21       Impact factor: 2.980

Review 6.  Glycemic control and treatment patterns in patients with heart failure.

Authors:  W H Wilson Tang
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

7.  Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.

Authors:  Magnus Dencker; Martin Stagmo; Mozhgan Dorkhan
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 8.  Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

Authors:  Janaka Karalliedde; Robin E Buckingham
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 9.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

10.  N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry.

Authors:  Seung Jei Park; Kyoung Im Cho; Sun Jae Jung; Sung Won Choi; Jae Won Choi; Dong Won Lee; Hyeon Gook Lee; Tae Ik Kim
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.